By John W. McEvoy and Cian Mangan
The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an area of interest. Numerous prospective studies and meta-analyses of these studies have demonstrated independent associations between hs-cTn concentrations and incident adverse CVD outcomes. Intriguingly, more recent data also indicate that commercial assays testing the T and I subunits of hs-cTn can provide independent and complementary prognostic information in primary prevention.
Read the full editorial comment here.
